Jim Simons
ALXN

Jim Simons’s Alexion Pharmaceuticals ALXN Stock Holding History

Jim Simons’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,147,521
Closed -$578M – 4040
2021
Q2 		$578M Sell
3,147,521
-180,600
-5% -$31M 0.72% 12
2021
Q1 		$509M Sell
3,328,121
-785,583
-19% -$122M 0.63% 19
2020
Q4 		$643M Sell
4,113,704
-643,539
-14% -$82.7M 0.7% 20
2020
Q3 		$544M Buy
4,757,243
+278,000
+6% +$30M 0.54% 31
2020
Q2 		$503M Buy
4,479,243
+715,741
+19% +$76M 0.43% 41
2020
Q1 		$338M Buy
3,763,502
+32,358
+0.9% +$3.18M 0.33% 58
2019
Q4 		$404M Buy
3,731,144
+881,477
+31% +$94.3M 0.31% 52
2019
Q3 		$279M Buy
2,849,667
+1,207,125
+73% +$136M 0.24% 85
2019
Q2 		$215M Buy
1,642,542
+840,742
+105% +$108M 0.19% 111
2019
Q1 		$108M Buy
801,800
+420,700
+110% +$52.3M 0.1% 237
2018
Q4 		$37.1M Buy
381,100
+313,200
+461% +$37M 0.04% 562
2018
Q3 		$9.44M Buy
+67,900
New +$8.52M 0.01% 1400
2018
Q1 		– Sell
-178,800
Closed -$21.4M – 3663
2017
Q4 		$21.4M Sell
178,800
-263,400
-60% -$32.1M 0.02% 899
2017
Q3 		$62M Buy
442,200
+229,900
+108% +$31.2M 0.07% 334
2017
Q2 		$25.8M Sell
212,300
-148,642
-41% -$17.3M 0.03% 705
2017
Q1 		$43.8M Buy
+360,942
New +$46.5M 0.06% 399
2015
Q4 		– Sell
-689,542
Closed -$108M – 3496
2015
Q3 		$108M Buy
689,542
+676,100
+5,030% +$123M 0.26% 53
2015
Q2 		$2.43M Sell
13,442
-300,510
-96% -$51.9M 0.01% 1933
2015
Q1 		$54.4M Buy
313,952
+161,400
+106% +$29.2M 0.12% 188
2014
Q4 		$28.2M Sell
152,552
-53,600
-26% -$9.9M 0.07% 337
2014
Q3 		$34.2M Sell
206,152
-39,400
-16% -$6.47M 0.09% 257
2014
Q2 		$38.4M Buy
+245,552
New +$38.8M 0.09% 250

Other funds holding ALXN

Brinker Capital Investments
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TD Ameritrade Investment Management
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CVA Family Office
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
Meeder Asset Management
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Jim Simons's ALXN Position: Q3 2021 in Review

Jim Simons sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 3,147,521 shares — an estimated $578M sold.

Jim Simons first reported a position in ALXN in Q2 2014 and held it in 22 quarters. The position peaked at $643M in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Jim Simons reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Jim Simons sold 3,147,521 Alexion Pharmaceuticals shares in Q3 2021, an estimated $578M.
  • Jim Simons first reported a position in Alexion Pharmaceuticals in Q2 2014 and held it in 22 quarters.
  • Jim Simons's Alexion Pharmaceuticals position peaked at $643M in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Renaissance Technologies's 13F filing for Q3 2021, filed 12 Nov 2021.